Feasibility, efficacy and acceptability of injected buprenorphine as treatment for opiate users who persist in injecting illicit heroin through opiate maintenance treatment - Buprenorphine Research into Injectable Opioids (BRIO)

Overview

No summary available.

Registry

who.int

Start Date

December 10, 2015

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•Aged 21\-60
•Currently in sublingual buprenorphine treatment for a minimum of 1 week this episode, and for a total of 12 months on methadone or buprenorphine
•Willing to attend for daily treatment
•Written, Informed consent to participate
•Persisting in injecting heroin \> 3 days per week as evidenced by client self\-report of regular injecting heroin use in the preceding 3 months, and of injecting heroin use on at least 50% of days in the past month
•evidence of regular injecting on clinical examination
•clinical formulation consistent with regular heroin use in the past 3 months, based on
•o Morphine positive urine samples
•o entries documented in clinical records,
•o examination findings documented in clinical records,

•Pregnant, breastfeeding, or planning to become pregnant (subjects at risk of pregnancy must agree to use contraception while receiving injectable treatment);
•Unable to attend the clinic daily;
•Advanced liver disease (jaundice, ascites, encephalopathy);
•Chronic airflow limitation, or other respiratory compromise producing dyspnea on mild exertion;
•Currently facing charges likely to lead to imprisonment.
•Cannot understand, speak or read English.
•Known allergy to buprenorphine
•Known hypersensitivity to any of the excipients.
•Precaution:
•Current alcohol or benzodiazepine dependence – prospective participants may require detoxification prior to induction onto parenteral buprenorphine.